Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy [13]

Leukemia and Lymphoma

Volumn 48, Issue 5, 2007, Pages 1053-1056

  Abdelhalim, Ahmed ^a   Barcos, Maurice ^a   Block, Annemarie W ^a   Sait, Sheila N J ^a   Starostik, Petr ^a   Wetzler, Meir ^a   Wang, Eunice S ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BCR ABL PROTEIN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD52 ANTIGEN; CD71 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTARABINE; DASATINIB; DOXORUBICIN; ETOPOSIDE; HLA DR ANTIGEN; HYDROXYUREA; IMATINIB; METHOTREXATE; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; MYELOPEROXIDASE; OCTAMER TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR PAX5;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; DRUG MEGADOSE; FATALITY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HLA MATCHING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; MYALGIA; NAUSEA AND VOMITING; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

BRAIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INHIBITORY CONCENTRATION 50; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PYRIMIDINES; REMISSION INDUCTION; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547427247     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701258370     Document Type: Letter

References (12)

1. Coutre, P le, Kreuzer, K. A., Pursche, S., Bonin, M., Leopold, T. and Baskaynak, G. (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol, 53, pp. 313-323.
2. Takayama, N., Sato, N., O'Brien, S. G., Ikeda, Y. and Okamoto, S. (2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol, 119, pp. 106-108.
3. Petzer, A. L., Gunsilius, E., Hayes, M., Stockhammer, G., Duba, H. C. and Scheller, F. (2002) Low concentrations of STI571 in the cerebrospinal fluid: A case report. Br J Haematol, 117, pp. 623-625.
4. Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J. and Paquette, R. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354, pp. 2531-2541.
5. Bristol-Myers-Squibb (2006) Sprycel (dasatinib) Prescriber Information and personal communication, E.S. Wang
6. Fleischhack, G., Jaehde, U. and Bode, U. (2005) Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet, 44, pp. 1-31.
7. Bleyer, W. A., Poplack, D. G. and Simon, R. M. (1978) "Concentration x time" methotrexate via a subcutaneous reservoir: A less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood, 51, pp. 835-842.
8. Schittenhelm, M. M., Shiraga, S., Schroeder, A., Corbin, A. S., Griffith, D. and Lee, F. Y. (2006) Dasatinib (BMS-354825), a dual SRC/ ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res, 66, pp. 473-481.
9. Song, L., Morris, M., Bagui, T., Lee, F. Y., Jove, R. and Haura, E. B. (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res, 66, pp. 5542-5548.
10. Chen, Z., Lee, F. Y. and Bhalla, K. N. (2006) Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol, 69, pp. 1527-1533.
11. Trevino, J. G., Summy, J. M., Lesslie, D. P., Parikh, N. U., Hong, D. S. and Lee, F. Y. (2006) Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol, 168, pp. 962-972.
12. Nam, S., Kim, D., Cheng, J. Q., Zhang, S., Lee, J. H. and Buettner, R. (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res, 65, pp. 9185-9189.